Hepion Pharmaceuticals, Inc. (HEPA): Price and Financial Metrics


Hepion Pharmaceuticals, Inc. (HEPA): $0.73

-0.05 (-6.11%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add HEPA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

HEPA Stock Price Chart Interactive Chart >

Price chart for HEPA

HEPA Price/Volume Stats

Current price $0.73 52-week high $1.33
Prev. close $0.78 52-week low $0.26
Day low $0.70 Volume 380,512
Day high $0.81 Avg. volume 1,767,246
50-day MA $0.48 Dividend yield N/A
200-day MA $0.60 Market Cap 55.63M

Hepion Pharmaceuticals, Inc. (HEPA) Company Bio


Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that has completed the Phase I clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and Tenofovir exalidex, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.


HEPA Latest News Stream


Event/Time News Detail
Loading, please wait...

HEPA Latest Social Stream


Loading social stream, please wait...

View Full HEPA Social Stream

Latest HEPA News From Around the Web

Below are the latest news stories about HEPION PHARMACEUTICALS INC that investors may wish to consider to help them evaluate HEPA as an investment opportunity.

Anti-Cancer Potential of Rencofilstat Expanded with Results from Preclinical Multiple Myeloma Studies

- Synergistic activity demonstrated with rencofilstat in combination with first line multiple myeloma drug, bortezomib - EDISON, N.J., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced positive

Yahoo | January 18, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

It's time to start off the day with a breakdown of the biggest pre-market stock movers making the news on Wednesday morning!

William White on InvestorPlace | January 11, 2023

Presentation of Preclinical Study Highlighting Anti-Cancer Activity of Rencofilstat in Combination with Proteosome Inhibitors

EDISON, N.J., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, announced that its research collaborator, Carlos Perez-Stable, PhD, from the University of Miami Miller School of Medicine and Miami Veterans Affairs/Research

Yahoo | January 10, 2023

Hepion Pharmaceuticals Receives $3.2 Million in Aggregate Non-Dilutive Funding

Approximately $2.9 Million from Sale of Its New Jersey State Net Operating Losses (“NOLs”), Plus $0.3 Million from Alberta Innovation Employment GrantEDISON, N.J., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chr

Yahoo | January 9, 2023

Hepion Pharmaceuticals to Present Phase 2a Rencofilstat Multiomics Data at NASH-TAG 2023

EDISON, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that an abstract highlighting its lead drug candidate, rencofilstat, will be presented at the NASH-TAG 2023 Conference,

Yahoo | January 5, 2023

Read More 'HEPA' Stories Here

HEPA Price Returns

1-mo 143.09%
3-mo 22.67%
6-mo 30.36%
1-year -25.52%
3-year -85.91%
5-year -99.53%
YTD 143.09%
2022 -73.66%
2021 -47.95%
2020 -59.14%
2019 -72.65%
2018 -90.28%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7206 seconds.